title: Cytokine-enhanced mixed lymphocyte reaction (MLR) in cord blood.
abstract: Although in cord blood (CB) transplantation graft-versus-host disease (GVHD) is reported to be less severe, GVHD may occur even in patients with HLA-identical sibling donors. This result shows that HLA typing can not entirely predict GVHD. The standard MLR with CB cells was either normal or slightly reduced compared with adult peripheral blood (PB) cells. We used two manipulations to increase the responses of CB cells to allo-antigens. The first was to treat the stimulator cells with cytokines, and the second to amplify weak proliferative responses by adding exogenous cytokines to MLR cultures (modified MLR). The stimulator cells were treated with both interferon-gamma (IFN-gamma) and IL-4. The responder cells were treated with both IL-2 and tumour necrosis factor-alpha (TNF-alpha). It is still to be determined whether or not this cytokine-enhanced MLR could be a possible predictor of GVHD. However, using these cytokines, 90% of CB could recognize allo-antigens, even if the standard MLR was negative.
authors.affiliation: Department of Pediatrics and Clinical Immunology, Mie University School of Medicine, Tsu, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Umemoto
authors.forename: E
authors.initials: E
authors.lastname: Azuma
authors.forename: M
authors.initials: M
authors.lastname: Hirayama
authors.forename: M
authors.initials: M
authors.lastname: Nagai
authors.forename: S
authors.initials: S
authors.lastname: Hiratake
authors.forename: J
authors.initials: J
authors.lastname: Qi
authors.forename: T
authors.initials: T
authors.lastname: Kumamoto
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Komada
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D000328:Adult; D005260:Female; D005312:Fetal Blood / Q000276:immunology*; D006086:Graft vs Host Disease / Q000276:immunology*; D006680:HLA Antigens / Q000032:analysis / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology / Q000494:pharmacology; D007376:Interleukin-2 / Q000276:immunology / Q000494:pharmacology; D015847:Interleukin-4 / Q000276:immunology / Q000494:pharmacology; D007519:Isoantigens / Q000276:immunology*; D011247:Pregnancy; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000494:pharmacology
chemical_list: D006680:HLA Antigens; D007376:Interleukin-2; D007519:Isoantigens; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007371:Interferon-gamma